Inhaled

  • We design and manufacture premium drug delivery devices for the treatment of respiratory diseases
  • The Group provides high quality products to our pharmaceutical customers:
    • Metered dose inhaler (MDI) valves
    • Contract manufacturing MDI and dry powder inhaler (DPI) products
    • Medical check valves
  • The market for inhaled drug delivery devices is forecast to reach US$43 bn in 2024, growing at an estimated CAGR of 3.3% between 2016 and 2024
  • The respiratory sector is one of the most highly regulated healthcare markets, with high barriers to entry
  • A number of key drugs are shortly coming "off patent", resulting in a number of new generic entrants and associated opportunities for Consort to supply both MDI and DPI devices
  • Although the traditional Western economies are mature and have slower growth, significant volume growth is being seen in emerging markets including the Brazilian, Russian, Indian and Chinese (BRIC) markets
  • The Group's strategy is to increase its already strong share of the respiratory market; this will include the development of new drug delivery devices and selling into new and developing geographical markets
  • The Group also offers customers finished dose formulation and manufacturing services and integrated drug/device development, formulation and manufacturing services
  • The Group will continue to leverage its continuous improvement activities to maintain its competitive position and support its customers as products move into the mature stage of their product life cycle

Injectable

  • Consort develops and manufacture auto-injectors including an innovative gas powered auto injector technology designed to support the safe operation of single-use syringes
  • These devices are capable of injecting high viscosity liquids and are marketed under the Syrina®, Lila® and Lapas® brands
  • We are working closely with a number of major pharmaceutical customers
  • The injectable drug delivery market is forecast to reach US$625 bn in 2021, growing at an estimated CAGR of 11.5% between 2016 and 2021
  • Growth is being driven by a large number of new drugs coming to the market for the first time that require delivery by injection
  • Whilst Bespak currently has a negligible share of this market, it is estimated that c.40% of all new drugs in development will be delivered parenterally and may, therefore, require some form of auto-injector
  • Many of these new "large molecule" biologic drugs are highly viscous and require specialist devices to enable them to be effectively administered, often by patients themselves in a non-clinical environment
  • The continued drive to greater self-administration with the associated improvements to patient compliance, patient outcomes and healthcare economics will create significant opportunities for the Group
  • Our Syrina®, Lila® and Lapas® range of auto-injectors positions the Group well to participate in this growing market
  • Our strategy is focused on the commercialisation of the existing pipeline in conjunction with the development of further IP and the exploitation of "innovation on demand" opportunities through our growing Innovation team in Cambridge
  • Endorsing this strategy, in FY2017 we signed a significant new master development agreement for our proprietary Vapoursoft® Syrina® auto-injector technology with a leading global biopharmaceutical company
  • Consort Medical intends to continue to move up the value chain by offering assembly and drug handling and will continue to look for additional, selective acquisitions in this area

Nasal

  • Consort has designed and developed a single-use device for nasal drug delivery
  • We are working with a number of pharmaceutical customers to support them on a variety of programmes
  • The nasal drug delivery technology market is forecast to reach US$64 bn in 2021, growing at an estimated CAGR of 6.5% between 2016 and 2021
  • Growth is being delivered from two main areas:
    • A number of existing branded drugs are coming off patent leading to generic entrants, all requiring their own delivery system as the original device associated with the branded drug is normally unavailable to them
    • Secondly, the nasal drug delivery route is extremely effective and a number of existing and new drugs are being reformulated to enable delivery in this way, increasing demand for this type of drug delivery product
  • The Group's strategy for the nasal market is focused on the delivery of Consort's existing development programmes
  • There are further opportunities utilising the Group's growing IP portfolio via a number of "innovation on demand" opportunities
  • The Group can also offer customers finished dose formulation and manufacturing services as well as integrated drug/device development, formulation and manufacturing services

Oral

  • The Group has a broad range of oral delivery capabilities and drug formulation and manufacturing services
  • Our capabilities include the manufacture of active pharmaceutical ingredients, tablets, capsules and liquids
  • We can package these products in bottles, blister packaging, sprays, pouches, ampoules and vials to specific customer requirement
  • The global oral drug delivery market is forecast to reach US$100 bn in 2018, having grown at an estimated CAGR of 9.4% between 2013 and 2018
  • The implementation of different technologies for oral drug delivery is changing the market scenario
  • There are high levels of attention from pharmaceutical companies due to the advantages that research can provide, such as reformulations, which can reposition drugs and delay patent expiry
  • The Group has a broad range of customer relationships and its strategy is to continue to drive organic growth in oral drug formulation and manufacture
  • This strategy also includes building relationships with new customers by offering premium drug formulation and manufacturing services

Point of care (POC)

  • Strategic development and manufacturing agreement with Atlas Genetics
  • Forecast to reach US$38 bn by 2022, growing at an estimated CAGR of 10.0% between 2017 and 2022
  • Market growth is being driven by the combined benefits of increased patient compliance, improved patient outcomes and lower cost of provision
  • Pharmaceutical companies are looking to exploit POC systems as part of a companion diagnostics strategy where drugs and tests are sold as combined "test and treat" packages
  • The Group's POC Diagnostics strategy is focused on the commercialisation of the Atlas Genetics device as a first stage penetration of the market
  • Substantial progress has been made in the last year in the POC card development, in conjunction with Bespak who separately provide development and manufacturing services to Atlas, and with the development of the card reader and assay tests
  • Following a successful outcome to this programme, Consort Medical intends to leverage the Group's development, manufacturing and regulatory know-how in order to grow its market share, possibly in conjunction with additional selective investments or acquisitions